Nalidixic acid sodium salt

Research use only, not for human use.

A synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum.

A synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial dna gyrase. (In Vitro):Nalidixic acid is against a variety of microorganisms, it is against with Escherichia coli, Pasteurella spp., Klebsiella pneuiiioniae, Aerobacter aeroyenes, Proteus spp., Salmonella spp., Shigella spp. and Brucella spp. with MIC values of 5.0-12.5 μg/ml, 0.5-2.5 μg/ml, 0.8-25.0 μg/ml, 1.0-25.0 μg/ml, 1.25-30.0 μg/ml, 8-3.2 μg/ml, and 7.5-10.0 μg/ml, respectively.(In Vivo):The in vivo activity of Nalidixic acid is most pronounced against Gram-negative bacteria, while Gram-positive organisms are generally more resistant. Maximal activity is observed against systemic infections caused by E. coli, A. aerobacter, Proteus mirabilis, Shigella fkxneri, the ED50 values are 25 mg/kg, 60 mg/kg, 50 mg/kg, and 62 mg/kg, respectively.The acute toxicity (LD50) of Nalidixic acid in mice following oral and parenteral administration is: oral, 3300 mg/kg; intravenous, 176 mg/kg, and subcutaneous, 500 mg/kg.

Nalidixic acid is against a variety of microorganisms, it is against with Escherichia coli, Pasteurella spp., Klebsiella pneuiiioniae, Aerobacter aeroyenes, Proteus spp., Salmonella spp., Shigella spp. and Brucella spp. with MIC values of 5.0-12.5 μg/ml, 0.5-2.5 μg/ml, 0.8-25.0 μg/ml, 1.0-25.0 μg/ml, 1.25-30.0 μg/ml, 8-3.2 μg/ml, and 7.5-10.0 μg/ml, respectively.

The in vivo activity of Nalidixic acid is most pronounced against Gram-negative bacteria, while Gram-positive organisms are generally more resistant. Maximal activity is observed against systemic infections caused by E. coli, A. aerobacter, Proteus mirabilis, Shigella fkxneri, the ED50 values are 25 mg/kg, 60 mg/kg, 50 mg/kg, and 62 mg/kg, respectively.The acute toxicity (LD50) of Nalidixic acid in mice following oral and parenteral administration is: oral, 3300 mg/kg; intravenous, 176 mg/kg; and subcutaneous, 500 mg/kg.

——

Cell Cycle/DNA Damage

Topoisomerase

Topo II

——

——

3374-05-8

254.22

C12H11N2NaO3

>98% (HPLC)

DMSO: 10 mM

[Na+].CCN1C=C(C([O-])=O)C(=O)C2=C1N=C(C)C=C2

——

(-20℃)

With Ice Pack

≥ 2 years